Novo Nordisk’s Wegovy Pill Gains UK Approval After Three Million US Prescriptions
LLY•MHRA approved Novo Nordisk’s Wegovy pill for adults with obesity (BMI ≥30) and overweight patients (BMI 27–30 plus comorbidity), extending its obesity portfolio in the UK. Uncertain NHS coverage has spurred a 55,000-patient private waitlist, and the US launch has generated over three million prescriptions, intensifying competition with Eli Lilly.
1. UK Approval Details
The UK’s Medicines and Healthcare products Regulatory Agency has authorised the daily oral Wegovy pill for adults with a BMI of 30 or above and overweight patients with a BMI of 27–30 plus at least one weight-related comorbidity, marking Novo Nordisk’s entry into the UK oral obesity market ahead of competitors.
2. NHS Coverage and Private Demand
NICE has not yet completed its cost-effectiveness review, leaving NHS coverage uncertain. This gap has led to 55,000 people joining private-sector waitlists for GLP-1RA treatments, underscoring strong demand and potential access hurdles within the public health system.
3. US Performance and Competitive Impact
Since its US launch, oral Wegovy has produced over three million prescriptions, a record rate of one script every five seconds. This robust uptake and comparable efficacy to weekly injections are poised to challenge Eli Lilly’s obesity franchise, particularly with Foundayo currently limited to the US market.
